

AGENDA

Monday 7 December 2020

5:00pm – 6:00pm AEDT

4:00pm - 5:00pm AEST

AGENDA ITEM	SPOKESPERSON/ATTACHMENT
<p>1. Welcome In attendance: Clare Scott, Damien Kee, Dianne Lindsay, Vera Terry, Nigel Frame, Kristen Nowak, Michael Brown, Richard Vines, Alison Trainer, Tim Price</p> <p>Apologies: David Thomas, Michelle Harrison, Phyllis Butow, David Goldstein, Dagmara Poprawski, Anna Pritchard</p> <p>CS: Welcome to the group.</p>	
<p>2. Conflicts of Interest</p>	<p>None declared</p>
<p>3. Minutes of previous meeting</p>	<p>Att: Minutes 13 Nov 2019 AT, RV</p>
<p>4. Executive Committee membership</p>	<p>CS: The composition of the Executive Committee Membership will be reviewed in early 2021.</p>
<p>5. Update on research projects and clinical trials</p> <ul style="list-style-type: none"> • MoST, AGCMC (VT/DT) • Rare Cancer Portal (DK) • Stafford Fox Rare Cancer Program (CS) • ICCon (AT) • Other projects and proposals 	<p>DK: Update on THINC-Rare and NOMINATOR. These have been published and/or presented at conferences (ASCO, COSA 2020)</p> <p>VT: Targeting 6000+ screened and 1000+ on trial over 5 years. 8 primary sites. Studies: RISC: 9/2020 n=1316; SMOC 9/2020 n =91; MoST: 9/2020 n=2812 (9/2019 n=1637); on therapy n=201 (n=185). (Now >3000 as of 11/2020). Follow-up unit has data demonstrating a separation of survival curves in favour of matched vs unmatched therapies. Future lung cancer study (TOGA & Roche collaboration: ASPIRATION) and blood cancers (Leukaemia and lymphoma, Stephen Lane and Hamish Scott).</p> <p>DK: ARC Portal overview. Details are available online at arcportal.org.au.</p> <p>CS: SFRCP – amendment to allow online consents</p> <p>AT: ICON – familial cancer collaborative project. Funding ended 2019. Grant submission to NHMRC led by Amanda Spurdle. Collection of all identified germline variants. Project manager funding. Collaborating with the AGHA. Younger patients will go into RISC.</p>
<p>6. Update on Rare Cancer Australia activities</p>	<p>RV: Vision 20/30 – looking at how the health system should change looking forward to leverage new technologies – 6 pillars (patients centred care, genomics, telehealth, AI, big data, rapid access to new testing and therapies). Strategy meetings to be run by Dorothy Keefe.</p>
<p>7. The COSA Tele-trial model and project (CS/SS)</p>	<p>CS: Tele-trial model (pilot) completed in 9/2020. Establishment of nodes/clusters across the country. Flowed into successful grant submissions to federal govt (Sabesan) and regional NSW/VIC (Underhill) to begin more widespread use of teletrials (150M in total).</p>
<p>8. International collaborations</p> <ul style="list-style-type: none"> • IRCI update and TRICEPS (CS) • NCI 	<p>CS: CS is the current chair of IRCI. An MRFF pre-call discussion (suitable to fund data entities such as TRICEPS) had been planned in 2020 prior to COVID) – TRICEPS will aim to collect data on patients receiving targeting drugs and pool this data internationally (regionally)</p>

	<p>to more rapidly identify effective matched drugs for rare cancer indications. To facilitate this the AGCMC data management committee meeting will organise a meeting in Q1/2 2021 and follow up with AGCMC/MTPConnect.</p> <p>NCI – rare cancer program - Leads are part of IRCI; similar to WEHI-SFRCP, will follow up synergies for 2021.</p>
<p>9. Other Business</p>	<p>KN: WA cancer registry have a report on rare cancer incidence and survival in preparation.</p>
<p>10. Planned Future Meetings The next Group AGM will coincide with the 2021 COSA ASM Working meeting Q1/Q2 2021</p>	